Optipharm.CO.,LTD Logo

Optipharm.CO.,LTD

Biotech for animal health and xenotransplantation using genetically engineered pig organs.

153710 | KO

Overview

Corporate Details

ISIN(s):
KR7153710009
LEI:
Country:
South Korea
Address:
충청북도 청주시 흥덕구 오송읍 오송생명6로 63, 청주시
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Optipharm.CO.,LTD is a biotechnology company specializing in animal health and advanced biomedical solutions. The company's core activities include animal disease diagnosis, the development of veterinary pharmaceuticals, bacteriophage-based products, and Virus-Like Particle (VLP) vaccines. A key focus for Optipharm is xenotransplantation, where it conducts pioneering research and development of genetically engineered pigs for organ transplantation to address human organ shortages. The company has achieved significant milestones in preclinical trials, including record survival times for primates that have received transplanted organs, positioning it at the forefront of regenerative medicine and organ transplant technology.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-03 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.3 MB
2025-07-31 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.8 KB
2025-06-30 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 27.4 KB
2025-06-10 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.9 KB
2025-05-19 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 26.6 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.3 MB
2025-05-02 00:00
Regulatory News Service
[기재정정]투자판단관련주요경영사항 (민군겸용 기술개발사업(형질전환돼지 기반 수혈가능 이종적혈구제제 기술개발) 국책과제 …
Korean 23.4 KB
2025-04-11 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 26.6 KB
2025-03-24 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 23.2 KB
2025-03-20 00:00
Regulatory News Service
[기재정정]신규시설투자등
Korean 11.4 KB
2025-03-14 00:00
Audit Report / Information
감사보고서제출
Korean 17.7 KB
2025-03-14 00:00
Annual Report
사업보고서 (2024.12)
Korean 1.5 MB
2025-03-07 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 12.6 KB
2025-03-07 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 154.7 KB

Automate Your Workflow. Get a real-time feed of all Optipharm.CO.,LTD filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Optipharm.CO.,LTD

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Optipharm.CO.,LTD via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Qurient Co., Ltd. Logo
Biopharma developing novel drugs for cancer, inflammation, and infectious diseases.
South Korea
115180
Rafael Holdings, Inc. Logo
Invests in and develops novel therapeutics for cancer and rare diseases.
United States of America
RFL
RaQualia Pharma Inc. Logo
An R&D firm discovering novel small molecules for out-licensing to pharma partners.
Japan
4579
Recruit Holdings Co., Ltd. Logo
Global provider of HR tech (Indeed), staffing services, and business SaaS solutions.
Japan
6098
RELMADA THERAPEUTICS, INC. Logo
A clinical-stage biotech developing novel therapies for CNS diseases and oncology.
United States of America
RLMD
Renascience Inc. Logo
Develops innovative drugs and AI-powered medical devices for aging and hereditary diseases.
Japan
4889
Rentracks CO.,LTD. Logo
A pay-per-performance ad network with a closed ASP and comprehensive web consulting services.
Japan
6045
Replimune Group, Inc. Logo
Clinical-stage biotech developing oncolytic immunotherapies to treat a broad range of cancers.
United States of America
REPL
ReproCELL Incorporated Logo
Offers stem cell tech, gene editing & drug discovery services for preclinical/clinical research.
Japan
4978
RESEARCH FRONTIERS INC Logo
Develops and licenses smart glass tech for instant light, UV, and heat control.
United States of America
REFR

Talk to a Data Expert

Have a question? We'll get back to you promptly.